Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold.
Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care. Eli Lilly's acquisition of SiteOne Therapeutics and STC-004 brings a once-daily NaV1.8 candidate, with early promising results but limited clinical data so far.
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Vertex's CF leadership, patent life, and addressable market, while Casgevy and Journavx add new growth avenues. VRTX valuation is justified by stable CF cash flows, a strong balance sheet, proven management, and a diversified pipeline with multiple near-term catalysts.
Vertex, Inc. (VERX) Q1 2025 Earnings Call Transcript
Vertex, Inc. (NASDAQ:VERX ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Joe Crivelli - Vice President of Investor Relations David DeStefano - President and Chief Executive Officer John Schwab - Chief Financial Officer Conference Call Participants Joshua Reilly - Needham & Company, LLC Christopher Quintero - Morgan Stanley Adam Hotchkiss - Goldman Sachs George Cruz - Citigroup Inc. Jake Roberge - William Blair & Company Kyle Aberasturi - BMO Capital Markets Alexander Sklar - Raymond James Financial, Inc. William Jellison - D.A. Davidson & Co. Rob Oliver - Robert W.
Compared to Estimates, Vertex (VERX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Vertex (VERX) Q1 Earnings and Revenues Top Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.15 per share a year ago.
Vertex On Track To Significantly Improve Revenue And Earnings By 2030
Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain management portfolio. The FDA approval of Journavx marks the beginning of a new era for the company. VRTX is not going to be the same company by 2030. I expect notable changes in its margin profile as the company diversifies into new markets.
Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why.
The company discloses narrower-than-expected access to its new painkiller.
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More
U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following their two-day meeting. The Dow Jones Industrial Average, S&P 500, and Nasdaq all fell.
Why Vertex Pharmaceuticals Stock Is Sinking Today
Shares of Vertex Pharmaceuticals (VRTX -11.69%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday.
Rising Costs Weigh on Vertex Q1 Earnings
Here's our initial take on Vertex Pharmaceuticals' (VRTX -0.27%) first-quarter financial report.
Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)
Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journavx look promising. Casgevy's progress is slow but uptake should improve going forward.
